Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Impilo on the establishment of Impilo Healthcare
Mandate

Vinge advises Impilo on the establishment of Impilo Healthcare

July 01, 2025 Private Funds

Vinge has advised Impilo with regulatory advice on the establishment of Impilo Healthcare. The fund will have EUR 320m in commitments.

Impilo is a Nordic investment company focused solely on investments in lower-mid market Nordic healthcare companies across the pharmaceuticals, MedTech, specialist pharma services and other healthcare and related services industries. Impilo has a well-diversified portfolio of healthcare investments and manages approximately EUR 2 billion of capital from leading international investors.

Vinges team consisted of Nils Unckel, Anton Sjökvist, Viktoria Wnuk and Isabelle Asserståhl.

Related

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025

Vinge advises Advania in connection with the acquisition of atNorth HPC AB

Vinge has advised Advania, one of the leading IT companies in the Nordic region, in connection with the acquisition of atNorth HPC AB. The acquisition strengthens Advania's presence within high-performance computing (HPC).
October 03, 2025